RNAimmune is a biotechnology startup specializing in messenger RNA (mRNA) technology. The company focuses on developing treatments for cancer, antibody therapies, rare diseases, and prophylactic vaccines. RNAimmune's proprietary technology uses mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company operates in the biotechnology and pharmaceutical markets, serving clients in the healthcare sector, including hospitals, research institutions, and pharmaceutical companies. RNAimmune generates revenue through the development and licensing of its mRNA-based therapies and vaccines. The company's leadership team includes industry veterans with extensive experience in drug development and pharmaceutical research, ensuring a strong foundation for innovation and growth.

Keywords: mRNA technology, cancer therapies, antibody treatments, rare diseases, vaccines, biotechnology, pharmaceutical, healthcare, drug development, innovation.